Reviewed by Michael Gill, B. Sc.
20 Borderline Personality Disorder Clinical Trials Near Me
Top Hospitals for Borderline Personality Disorder Clinical Trials
Image of Icahn School of Medicine at Mount Sinai in New York.
Icahn School of Medicine at Mount Sinai
New York
2Active Trials
4All Time Trials for Borderline Personality Disorder
2011First Borderline Personality Disorder Trial
Image of Rutgers University in New Jersey.
Rutgers University
Piscataway
2Active Trials
2All Time Trials for Borderline Personality Disorder
2010First Borderline Personality Disorder Trial
Top Cities for Borderline Personality Disorder Clinical Trials
Image of New York in New York.
New York
3Active Trials
Icahn School of Medicine at Mount SinaiTop Active Site
Top Treatments for Borderline Personality Disorder Clinical Trials
Treatment Name
Active Borderline Personality Disorder Clinical Trials
All Time Trials for Borderline Personality Disorder
First Recorded Borderline Personality Disorder Trial
Patients with BPD assigned to the trial of 10 active tDCS sessions followed by psychotherapy
1
1
2021
Psilocybin
1
1
2022
Amygdala Neurofeedback
1
1
2022
STAIR
1
1
2022
Cognitive Reappraisal by Distancing
1
1
2021

What Are Borderline Personality Disorder Clinical Trials?

Borderline personality disorder is a mental health condition in which patients have trouble controlling and regulating emotions. Patients also experience mood swings and unstable relationships as loss of emotional control leads to increased impulsivity. Such individuals are at a higher risk of suicide and self-destructive behavior.

The current borderline personality clinical trials focus on analyzing and comparing different drugs and therapies for treatment.

Why Is Borderline Personality Disorder Being Studied Through Clinical Trials?

Around 1.4% of the adult population in the U.S. experiences BPD. Nearly 75% of people diagnosed with BPD are women. However, recent research suggests that men may be equally affected by BPD but are commonly misdiagnosed with PTSD or depression.

The causes of BPD are not clearly identified, but it could be a combination of genetics, environmental, or neurological factors. BPD leads to unstable self-image and relationships, chronic feelings, intense anger, and self-harming behavior.

What Are The Types of Treatments Available For Borderline Personality Disorder?

There are multiple treatments available for borderline personality disorder. A double-blind, placebo-controlled study conducted in 2018 evaluated the safety and efficacy of Brexpiprazole in adults with borderline personality disorder (BPD). Brexpiprazole has distinctive properties that make it a promising option for patients with BPD. Brexpiprazole is a novel D2 partial agonist, has an affinity for 5-HT1A, acts as an antagonist of the noradrenergic α1/2 receptor, partial agonist for D3, and antagonist for 5-HT2A (37-39). In addition, because of low rates of side effects, Brexpiprazole should be a well-tolerated and, in fact, desired medication approach to BPD.

Other studies focus on the application of different behavioral programs as interventions for people with BPD.

What Are Some Recent Breakthrough Clinical Trials For Borderline Personality Disorder?

2020: Pharmacotherapy for Borderline Personality Disorder - the study reviewed seven new randomized controlled trials (RCTs) for evaluating continued drug treatments in patients with BPD. The new findings do not support fluoxetine as a treatment option for suicide and self-harm prevention. Moreover, lamotrigine in routine care shows no beneficial effects. Thus, more research is required for commonly used substances for BPD.

2020: Psychological Therapies - this study assessed the beneficial and harmful effects of psychological therapies for people with BPD. More than 16 different kinds of psychotherapy were included, mostly dialectical behavior therapy (DBT) and mentalization-based treatment (MBT). Results showed beneficial effects on all primary outcomes in favor of BPD‐tailored psychotherapy compared with TAU (Treatment As Usual).

Who Are Some Of The Key Opinion Leaders / Researchers / Institutions Conducting Borderline Personality Disorder Clinical Trial Research?

Marsha Linehan, PhD

Marsha Linehan, PhD is the Director Emeritus of the Behavioral Research and Therapy Clinics, a consortium of research projects developing new treatments and evaluating their efficacy for severely disordered and multi-diagnostic and suicidal populations.

McLean Hospital

The Gunderson Personality Disorders Institute at McLean Hospital creates awareness and training for evidence-based treatments for borderline personality disorder (BPD) and accompanying psychiatric conditions.

About The Author

Michael Gill preview

Michael Gill - B. Sc.

First Published: October 26th, 2021

Last Reviewed: October 29th, 2022

Michael Gill holds a Bachelors of Science in Integrated Science and Mathematics from McMaster University. During his degree he devoted considerable time modeling the pharmacodynamics of promising drug candidates. Since then, he has leveraged this knowledge of the investigational new drug ecosystem to help his father navigate clinical trials for multiple myeloma, an experience which prompted him to co-found Power Life Sciences: a company that helps patients access randomized controlled trials.

References1 George MS, Lisanby SH, Avery D, McDonald WM, Durkalski V, Pavlicova M, Anderson B, Nahas Z, Bulow P, Zarkowski P, Holtzheimer PE 3rd, Schwartz T, Sackeim HA. Daily left prefrontal transcranial magnetic stimulation therapy for major depressive disorder: a sham-controlled randomized trial. Arch Gen Psychiatry. 2010 May;67(5):507-16. doi: 10.1001/archgenpsychiatry.2010.46. https://pubmed.ncbi.nlm.nih.gov/204398322 Stoffers-Winterling JM, Storebø OJ, Pereira Ribeiro J, Kongerslev MT, Völlm BA, Mattivi JT, Faltinsen E, Todorovac A, Jørgensen MS, Callesen HE, Sales CP, Schaug JP, Simonsen E, Lieb K. Pharmacological interventions for people with borderline personality disorder. Cochrane Database Syst Rev. 2022 Nov 14;11:CD012956. doi: 10.1002/14651858.CD012956.pub2. Review. https://pubmed.ncbi.nlm.nih.gov/363751743 George MS, Wassermann EM, Williams WA, Callahan A, Ketter TA, Basser P, Hallett M, Post RM. Daily repetitive transcranial magnetic stimulation (rTMS) improves mood in depression. Neuroreport. 1995 Oct 2;6(14):1853-6. https://pubmed.ncbi.nlm.nih.gov/85475834 Pascual-Leone A, Rubio B, Pallardó F, Catalá MD. Rapid-rate transcranial magnetic stimulation of left dorsolateral prefrontal cortex in drug-resistant depression. Lancet. 1996 Jul 27;348(9022):233-7. https://pubmed.ncbi.nlm.nih.gov/86842015 Linehan MM, Comtois KA, Murray AM, Brown MZ, Gallop RJ, Heard HL, Korslund KE, Tutek DA, Reynolds SK, Lindenboim N. Two-year randomized controlled trial and follow-up of dialectical behavior therapy vs therapy by experts for suicidal behaviors and borderline personality disorder. Arch Gen Psychiatry. 2006 Jul;63(7):757-66. Erratum in: Arch Gen Psychiatry. 2007 Dec;64(12):1401. https://pubmed.ncbi.nlm.nih.gov/168188656 Downar J, Geraci J, Salomons TV, Dunlop K, Wheeler S, McAndrews MP, Bakker N, Blumberger DM, Daskalakis ZJ, Kennedy SH, Flint AJ, Giacobbe P. Anhedonia and reward-circuit connectivity distinguish nonresponders from responders to dorsomedial prefrontal repetitive transcranial magnetic stimulation in major depression. Biol Psychiatry. 2014 Aug 1;76(3):176-85. doi: 10.1016/j.biopsych.2013.10.026. Epub 2013 Nov 28. Erratum in: Biol Psychiatry. 2014 Sep 1;76(5):430. https://pubmed.ncbi.nlm.nih.gov/243886707 Liston C, Chen AC, Zebley BD, Drysdale AT, Gordon R, Leuchter B, Voss HU, Casey BJ, Etkin A, Dubin MJ. Default mode network mechanisms of transcranial magnetic stimulation in depression. Biol Psychiatry. 2014 Oct 1;76(7):517-26. doi: 10.1016/j.biopsych.2014.01.023. Epub 2014 Feb 5. https://pubmed.ncbi.nlm.nih.gov/246295378 Abdallah CG, Averill LA, Collins KA, Geha P, Schwartz J, Averill C, DeWilde KE, Wong E, Anticevic A, Tang CY, Iosifescu DV, Charney DS, Murrough JW. Ketamine Treatment and Global Brain Connectivity in Major Depression. Neuropsychopharmacology. 2017 May;42(6):1210-1219. doi: 10.1038/npp.2016.186. Epub 2016 Sep 8. https://pubmed.ncbi.nlm.nih.gov/276045669 Gärtner M, Aust S, Bajbouj M, Fan Y, Wingenfeld K, Otte C, Heuser-Collier I, Böker H, Hättenschwiler J, Seifritz E, Grimm S, Scheidegger M. Functional connectivity between prefrontal cortex and subgenual cingulate predicts antidepressant effects of ketamine. Eur Neuropsychopharmacol. 2019 Apr;29(4):501-508. doi: 10.1016/j.euroneuro.2019.02.008. Epub 2019 Feb 26. https://pubmed.ncbi.nlm.nih.gov/3081954910 McMain SF, Guimond T, Streiner DL, Cardish RJ, Links PS. Dialectical behavior therapy compared with general psychiatric management for borderline personality disorder: clinical outcomes and functioning over a 2-year follow-up. Am J Psychiatry. 2012 Jun;169(6):650-61. doi: 10.1176/appi.ajp.2012.11091416. https://pubmed.ncbi.nlm.nih.gov/22581157